NRX Pharmaceuticals(US:NRXP) Prnewswireยท2025-08-13 22:06Core Viewpoint - NRx Pharmaceuticals is preparing to release its second quarter 2025 financial results and will host a conference call to discuss these results, highlighting its ongoing developments in the biopharmaceutical sector focused on central nervous system disorders [1][2]. Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company that develops therapeutics targeting central nervous system disorders, including suicidal depression, chronic pain, and PTSD [3]. - The company is working on two main products: NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone [3]. - NRX-100 has received Fast Track Designation for treating suicidal ideation in depression, including bipolar depression, while NRX-101 has been granted Breakthrough Therapy Designation for treating suicidal bipolar depression [3]. Recent Developments - NRx Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application (NDA) for NRX-100, seeking to utilize the Commissioner's National Priority Voucher Program for treating suicidal depression [4]. - The NDA filing is based on results from well-controlled clinical trials conducted in collaboration with the US National Institutes of Health and the Government of France [4].